We are live on
!
Find out more
Ensign Peak Advisors Portfolio holdings
AUM
$53.7B
1-Year Est. Return
29.47%
This Fund
S&P 500
This Quarter
Est. Return
+4.38%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
–
AUM
$56.3B
AUM Growth
-$596M
(-1%)
Cap. Flow
-$1.62B
Cap. Flow
% of AUM
-2.89%
Top 10 Holdings %
Top 10 Hldgs %
32.29%
Holding
1,743
New
37
Increased
427
Reduced
443
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$304M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$156M |
| 3 |
Monolithic Power Systems
MPWR
|
+$134M |
| 4 |
LyondellBasell Industries
LYB
|
+$128M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$101M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$374M |
| 2 |
Microsoft
MSFT
|
+$253M |
| 3 |
Apple
AAPL
|
+$200M |
| 4 |
Broadcom
AVGO
|
+$198M |
| 5 |
Meta Platforms (Facebook)
META
|
+$193M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.94% |
| 2 | Financials | 13.84% |
| 3 | Healthcare | 12.35% |
| 4 | Consumer Discretionary | 10.61% |
| 5 | Communication Services | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
XP
XP
$8.43B
| $127K | ﹤0.01% |
+10,700
| New | +$168K |
|
1702
Olema Pharmaceuticals
OLMA
$977M
| $110K | ﹤0.01% |
18,849
| – | – |
|
1703
Sterling Infrastructure
STRL
$15.2B
| $107K | ﹤0.01% |
+635
| New | +$110K |
|
1704
iQIYI
IQ
$1.19B
| $88.7K | ﹤0.01% |
44,150
| – | – |
|
|
FLNA
1705
Filana Therapeutics
FLNA
$42M
| $86.1K | ﹤0.01% |
36,496
+20,100
| +123% | +$353K |
|
1706
NIO
NIO
$11.9B
| $75.7K | ﹤0.01% |
17,371
-141,050
| -89% | -$718K |
|
1707
Keros Therapeutics
KROS
$197M
| $5.38K | ﹤0.01% |
340
-71,400
| -100% | -$3.71M |
|
1708
US Physical Therapy
USPH
$1.22B
| $621 | ﹤0.01% |
7
| – | – |
|
1709
Agilon Health
AGL
$1.55B
| – | – |
-5,637
| Closed | -$554K |
|
1710
ATN International
ATNI
$365M
| – | – |
-13,377
| Closed | -$433K |
|
1711
Cabaletta Bio
CABA
$427M
| – | – |
-36,873
| Closed | -$174K |
|
1712
Cullinan Oncology
CGEM
$1.06B
| – | – |
-148,773
| Closed | -$2.49M |
|
1713
Corbus Pharmaceuticals
CRBP
$165M
| – | – |
-45,364
| Closed | -$936K |
|
|
FYBR
1714
DELISTED
Frontier Communications
FYBR
| – | – |
-37,055
| Closed | -$1.32M |
|
1715
IN8bio
INAB
$10.3M
| – | – |
-27,639
| Closed | -$224K |
|
1716
Liberty Broadband Class C
LBRDK
$4.89B
| – | – |
-40,649
| Closed | -$3.14M |
|
1717
Lightwave Logic
LWLG
$824M
| – | – |
-100,552
| Closed | -$278K |
|
1718
Methode Electronics
MEI
$458M
| – | – |
-25,341
| Closed | -$303K |
|
1719
Mineralys Therapeutics
MLYS
$2.32B
| – | – |
-125,000
| Closed | -$1.51M |
|
1720
MaxCyte
MXCT
$108M
| – | – |
-59,013
| Closed | -$230K |
|
1721
NewAmsterdam Pharma
NAMS
$3.26B
| – | – |
-245,571
| Closed | -$4.08M |
|
1722
Nu Skin
NUS
$257M
| – | – |
-19,976
| Closed | -$147K |
|
1723
OraSure Technologies
OSUR
$273M
| – | – |
-52,519
| Closed | -$224K |
|
1724
Sana Biotechnology
SANA
$882M
| – | – |
-72,050
| Closed | -$300K |
|
1725
TTEC Holdings
TTEC
$124M
| – | – |
-22,808
| Closed | -$134K |
|
Similar funds
SCP
Ensign Peak Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Ensign Peak Advisors held 1,743 positions worth $56.3B, down 1% from $56.9B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Trading was light in Q4 2024: portfolio turnover was 4.1%. Ensign Peak Advisors opened 37 new positions and exited 34, leaving the 1,743-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 30% a quarter earlier, followed by Financials and Healthcare.
- Ensign Peak Advisors's largest Q4 2024 buy was State Street SPDR S&P 500 ETF Trust: 515,457 shares worth $302M.
- Ensign Peak Advisors added most to iShares Core S&P 500 ETF in Q4 2024, an estimated $156M increase.
- Ensign Peak Advisors's biggest Q4 2024 reduction was NVIDIA, cutting an estimated $374M.
- Ensign Peak Advisors fully exited NewAmsterdam Pharma in Q4 2024, selling an estimated $4.08M.
- Ensign Peak Advisors's ten largest holdings make up 32% of its $56.3B portfolio in Q4 2024.
- Ensign Peak Advisors opened 37 new positions and closed 34 in Q4 2024.
- Ensign Peak Advisors's portfolio value fell 1% quarter-over-quarter to $56.3B.
Based on Ensign Peak Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.